FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2013140369> ?p ?o ?g. }

• W2013140369 endingPage "19" @default.
• W2013140369 startingPage "16" @default.
• W2013140369 abstract "<h2>Abstract</h2> Thrombolytic therapy has been shown to reduce mortality and morbidity after acute myocardial infarction. Therapeutic benefit seems to be directly correlated with completeness of reperfusion (Thrombolysis in Myocardial Infarction [TIMI] grade 3 flow) of the infarct-related coronary artery, as well as the timeliness of reperfusion. To determine which regimen of reteplase (r-PA), a deletion mutant of wild-type tissue plasminogen activator (t-PA), is most effective for clinical thrombolysis, several reteplase regimens were compared with the most successful standard regimens of recombinant t-PA (alteplase) in 2 large-scale, randomized studies. All patients received aspirin and intravenous heparin. In the Reteplase Angiographic Phase II International Dose Finding Trial (RAPID-1), results in 606 randomized patients showed that a 10 + 10 U double bolus of reteplase was more effective than a 15 U single bolus, a 10 + 5 double bolus, or conventional alteplase (100 mg over 3 hours). In the Reteplase versus Alteplase Patency Investigation During Acute Myocardial Infarction (RAPID-2) trial, results in 324 patients showed that significantly more patients achieved patency of the infarct-related artery (TIMI grade 2 or 3 flow) at 90 minutes with reteplase (10 + 10 U double bolus) than with accelerated alteplase (100 mg over 90 minutes): 83.4% versus 73.3%, respectively (p = 0.03). The incidence of complete patency (TIMI grade 3 flow) at 90 minutes was likewise greater with reteplase than with accelerated alteplase (59.9% vs 45.2%, respectively; p=0.01). At 60 minutes, the incidence of TIMI grade 2 or 3 flow was also significantly higher with reteplase than with alteplase (81.8% vs 66.1%, respectively; p=0.01), as was the incidence of TIMI grade 3 flow (51.2% vs 37.4%, respectively; p <0.031). The 35-day mortality rate was 4.1% for reteplase and 8.4% for alteplase (p = not significant). Reteplase and alteplase did not differ significantly with regard to the occurrence of severe bleeding (12.4% vs 9.7%, respectively) or hemorrhagic stroke (1.2% vs 1.9%, respectively). The results of these trials show that reteplase, given as a 10 + 10 U double bolus, achieves significantly higher rates of early reperfusion of the infarct-related coronary artery and is associated with significantly fewer acute coronary interventions when compared with front-loaded alteplase. The benefits of reteplase are achieved without any apparent increased risk of complications. © <i>1996 by Excerpta Medica, Inc</i>. Am J Cardiol 1996;78(suppl 12A):16–19" @default.
• W2013140369 created "2016-06-24" @default.
• W2013140369 creator A5017098029 @default.
• W2013140369 creator A5022972529 @default.
• W2013140369 creator A5049936296 @default.
• W2013140369 creator A5051005374 @default.
• W2013140369 creator A5086729202 @default.
• W2013140369 creator A5089202774 @default.
• W2013140369 date "1996-12-01" @default.
• W2013140369 modified "2023-10-18" @default.
• W2013140369 title "Patency Trials With Reteplase (r-PA): What Do They Tell Us?" @default.
• W2013140369 cites W1596397105 @default.
• W2013140369 cites W1963950792 @default.
• W2013140369 cites W1964788971 @default.
• W2013140369 cites W1978370228 @default.
• W2013140369 cites W1984633053 @default.
• W2013140369 cites W1991415109 @default.
• W2013140369 cites W1995743565 @default.
• W2013140369 cites W2005261732 @default.
• W2013140369 cites W2026153571 @default.
• W2013140369 cites W2036707395 @default.
• W2013140369 cites W2039160954 @default.
• W2013140369 cites W2056991975 @default.
• W2013140369 cites W2059787662 @default.
• W2013140369 cites W2087480868 @default.
• W2013140369 cites W2116528972 @default.
• W2013140369 cites W2152510274 @default.
• W2013140369 cites W2333920681 @default.
• W2013140369 cites W2409934099 @default.
• W2013140369 cites W3021473981 @default.
• W2013140369 cites W3025057188 @default.
• W2013140369 doi "https://doi.org/10.1016/s0002-9149(96)00738-2" @default.
• W2013140369 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8990406" @default.
• W2013140369 hasPublicationYear "1996" @default.
• W2013140369 type Work @default.
• W2013140369 sameAs 2013140369 @default.
• W2013140369 citedByCount "11" @default.
• W2013140369 countsByYear W20131403692015 @default.
• W2013140369 crossrefType "journal-article" @default.
• W2013140369 hasAuthorship W2013140369A5017098029 @default.
• W2013140369 hasAuthorship W2013140369A5022972529 @default.
• W2013140369 hasAuthorship W2013140369A5049936296 @default.
• W2013140369 hasAuthorship W2013140369A5051005374 @default.
• W2013140369 hasAuthorship W2013140369A5086729202 @default.
• W2013140369 hasAuthorship W2013140369A5089202774 @default.
• W2013140369 hasConcept C126322002 @default.
• W2013140369 hasConcept C164705383 @default.
• W2013140369 hasConcept C2777995511 @default.
• W2013140369 hasConcept C2779581417 @default.
• W2013140369 hasConcept C2780790693 @default.
• W2013140369 hasConcept C2781413609 @default.
• W2013140369 hasConcept C42219234 @default.
• W2013140369 hasConcept C43376680 @default.
• W2013140369 hasConcept C500558357 @default.
• W2013140369 hasConcept C71924100 @default.
• W2013140369 hasConceptScore W2013140369C126322002 @default.
• W2013140369 hasConceptScore W2013140369C164705383 @default.
• W2013140369 hasConceptScore W2013140369C2777995511 @default.
• W2013140369 hasConceptScore W2013140369C2779581417 @default.
• W2013140369 hasConceptScore W2013140369C2780790693 @default.
• W2013140369 hasConceptScore W2013140369C2781413609 @default.
• W2013140369 hasConceptScore W2013140369C42219234 @default.
• W2013140369 hasConceptScore W2013140369C43376680 @default.
• W2013140369 hasConceptScore W2013140369C500558357 @default.
• W2013140369 hasConceptScore W2013140369C71924100 @default.
• W2013140369 hasIssue "12" @default.
• W2013140369 hasLocation W20131403691 @default.
• W2013140369 hasLocation W20131403692 @default.
• W2013140369 hasOpenAccess W2013140369 @default.
• W2013140369 hasPrimaryLocation W20131403691 @default.
• W2013140369 hasRelatedWork W1964788971 @default.
• W2013140369 hasRelatedWork W1986689269 @default.
• W2013140369 hasRelatedWork W1989760200 @default.
• W2013140369 hasRelatedWork W2031157079 @default.
• W2013140369 hasRelatedWork W2063187204 @default.
• W2013140369 hasRelatedWork W2073278282 @default.
• W2013140369 hasRelatedWork W2307773399 @default.
• W2013140369 hasRelatedWork W2332320572 @default.
• W2013140369 hasRelatedWork W2885168853 @default.
• W2013140369 hasRelatedWork W2413908167 @default.
• W2013140369 hasVolume "78" @default.
• W2013140369 isParatext "false" @default.
• W2013140369 isRetracted "false" @default.
• W2013140369 magId "2013140369" @default.
• W2013140369 workType "article" @default.